Bracco molecular imaging subsidiary Blue Earth Diagnostics is directing attention to several presentations at the upcoming annual meeting of the American Society for Radiation Oncology (ASTRO) later this week in Chicago.
Several studies at ASTRO 2019 will feature clinical experience with the company's Axumin (fluciclovine F-18) PET radiopharmaceutical, including a talk that will provide full results from the Fluciclovine (F-18) PET/CT in Biochemical Recurrence of Prostate Cancer (FALCON) trial.
In addition, researchers from the Technical University of Munich in Germany will report their initial clinical experience with using Blue Earth's "radiohybrid" prostate-specific membrane antigen (F-18 rhPSMA-7) imaging agent, the company said.
